Analysts weigh in with confidence on two biotech stocks blasting through the roof this week.
The hedge fund guru’s Q2 moves added ECYT gains to his pocket while saving him greater losses in VRX.
Cowen sees hope for ECYT amid acquisition refocus; H.C.
